Takeda

Cell and gene therapy concept
#Cell and gene therapy #Eli Lilly #FDA #Novo Nordisk #Takeda #Tregs

A bright future for advanced therapies 

2025 was a difficult year for cell and gene therapies (CGTs), as multiple companies discontinued their cell therapy efforts, including Galapagos, Novo Nordisk and Takeda, despite significant financial losses as a result. The complexity and expense of manufacturing the treatments has meant that even when they are approved, the therapies do not always reach the relevant patients. This,… Read More

#Exclusive Content

Blood cells
#Monoclonal antibodies #Phase II trial #Rare disease #Takeda

NEJM data support Takeda’s treatment for ITP

The New England Journal of Medicine (NEJM) has published final results from a Phase II study evaluating Takeda’s mezagitamab (TAK-079), an investigational treatment option for patients with primary immune thrombocytopenia (ITP).  The NEJM-published data showed patients treated with mezagitamab achieved:  … Read More

#News

Plaque Psoriasis
#Dermatology #Phase III trial #Psoriasis #Takeda

Landmark results support TYK2 inhibitor as a leading psoriasis treatment

Takeda’s oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) has shown promise to deliver clear skin in a once-daily pill.  Phase III studies in adults with moderate-to-severe plaque psoriasis (PsO) have demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA)… Read More

#News

Handshake jigsaw puzzle
#Cancer research #Innovent #Takeda

Takeda and Innovent Biologics partner to develop tumour medicines

Pharmaceutical company Takeda has announced it has entered a global strategic partnership with biotechnology company Innovent Biologics to develop next-generation medicines for cancer tumours.  The agreement will see the development, manufacturing and commercialisation of two late-stage oncology medicines, IBI363 and IBI343, worldwide outside of Greater China. IBI63… Read More

#Business & Investment #News

Molecular,Model,Of,Antibody
#Antibody #Clinical trials #Haematology #Harvard Medical School #ITP #Monoclonal antibodies #Platelet biology #Takeda

Mezagitamab and the future of ITP treatment

The International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress took place in Washington DC from 21-25 June 2025. At this event, Takeda presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody (mAb), in patients with persistent or chronic primary immune thrombocytopenia… Read More

#Exclusive Content

#Antibody drug conjugate (ADC) #Big pharma #Drug development #Drug discovery #Heidelberg Pharma #Takeda #Therapeutic Antibodies

A global overview of therapeutic antibody development

DDW’s Megan Thomas takes a wide-angle look at the sector and speaks to experts and thought leaders about their predictions for therapeutic antibodies in 2025. Clinical advancements Marcelo Freire, Vice President of Global Medical Affairs, Therapeutic Area Head of Gastroenterology at Takeda, comments on monoclonal antibodies (mAbs) from a gastro… Read More

#Business & Investment #Exclusive Content

Kidneys
#Clinical trial #Kidney disease #Nephrology #Takeda #Vera Therapeutics

Positive news for IgAN treatment presented at Kidney Week

Positive data from two trials in immunoglobulin A nephropathy (IgAN) were shared at the American Society of Nephrology Kidney Week 2024 in San Diego, California. Vera Therapeutics announced data from its ORIGIN Phase IIb trial of atacicept that showed stabilised kidney function through 96 weeks of… Read More

#News #Trending News

Immune thrombocytopenia test
#Events #ITP #Monoclonal antibodies #Phase II trial #Takeda

Favourable results for mAb in bleeding disorder shared at ISTH

Takeda has shared positive results from its Phase IIb study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterised by the accelerated destruction of platelets in blood, resulting… Read More

#News

Stem cell transplant
#China #Cytomegalovirus #Phase III trial #Stem cell transplant #Takeda #Transplant

China’s NMPA okays maribavir for post-transplant cytomegalovirus

Takeda’s Livtencity (maribavir) has been approved in China for the treatment of adult patients with post-hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) cytomegalovirus (CMV) infection/disease. It has been licensed by the National Medical Products Administration (NMPA) in cases where the infection is resistant… Read More

#News #Regulatory

Blood cells
#FDA #Gene mutation #Genetic diseases #Rare disease #Takeda

First therapy for very rare blood clotting disorder gets US greenlight

Takeda’s Adzynma has become the first recombinant protein product approved in the US for prophylactic or on-demand enzyme replacement therapy (ERT) for congenital thrombotic thrombocytopenic purpura (cTTP). A very rare, inherited blood clotting disorder, cTTP is caused by a disease-causing mutation in the ADAMTS13 gene, which… Read More

#Editor's Choice #News #Regulatory

Blood cells
#blood #Haematology #Phase III trial #Takeda #Trial data

Promising new drug for chronic blood clotting disorder

Takeda has revealed favourable interim results from its Phase III crossover trial evaluating the safety and efficacy of TAK-755 (recombinant ADAMTS13) replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura (cTTP). cTTP is an ultra-rare, chronic and debilitating blood clotting disorder caused by a… Read More

#News

Mosquito
#Immunology / Virology & Vaccines #MHRA #Phase III trial #Takeda #Vaccine candidate

UK approval for dengue virus vaccine candidate

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda’s vaccine candidate Qdenga for active immunisation against dengue infection from four years of age.  Dengue is the fastest spreading mosquito-borne virus and was recognised by the World Health Organization (WHO) in 2019… Read More

#News

#Drug approvals #Lung cancer #Takeda

Takeda’s cancer drug gets nod from MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to Takeda’s EXKIVITY (mobocertinib) for patients in Great Britain with a rare and aggressive form of non-small cell lung cancer (NSCLC).   The authorisation means that EXKIVITY (mobocertinib) will be made available as a… Read More

#News

#Covid-19 #Daiichi Sankyo #Drug discovery #Fujifilm Toyama Chemical #Japan #Takeda

Japanese drug development: Where is the innovation? 

Lu Rahman looks at how opportunities are growing in Japanese drug development and where innovation is coming from. Japan is a fascinating drug discovery and development market. A strong pharmaceutical sector (some reports place it second globally behind the US), an ageing population and a tranche of expertise, put the… Read More

#Editor's Choice #Exclusive Content #Market Reports